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OBJECTIVES We examined whether the combination of an angiotensin-converting enzyme (ACE)
inhibitor and an angiotensin II receptor blocker (ARB) synergistically mediates coronary
vasodilation and improves myocardial metabolic and contractile dysfunction in ischemic
hearts.
BACKGROUND Either an ACE inhibitor or ARB mediates coronary vasodilation in ischemic hearts.
METHODS In dogs with myocardial ischemia, we infused an ACE inhibitor (temocaprilat,
10 g/kg/min) or ARB (RNH-6270, 10 g/kg/min) into the coronary artery.
RESULTS Perfusion pressure of the left anterior descending coronary artery was reduced from 104  8
to 42  2 mm Hg, so that coronary blood flow (CBF) decreased to one-third of the baseline
value. Ten minutes after starting the infusion of temocaprilat, the cardiac bradykinin level
increased (from 32  6 to 98  5 pg/ml). Coronary blood flow (29  2 to 44  3 ml/100
g/min) and the cardiac level of nitric oxide (NO) (7.8 1.9 to 17.5 3.2 m) also increased,
with these changes being attenuated by either N-nitro-L-arginine methyl ester or HOE140.
RNH-6270 alone caused a modest increase in CBF (34  3 ml/100 g/min), with no increase
in the cardiac NO or bradykinin levels. Both temocaprilat and RNH-6270 caused a further
increase in both CBF (51  4 ml/100 g/min) and cardiac NO levels, without increasing the
bradykinin level, and these changes were inhibited by HOE140. In the nonischemic heart,
RNH-6270 augmented bradykinin-induced increases in CBF.
CONCLUSIONS The combination of an ACE inhibitor and ARB mediates greater increases in CBF and more
potent cardioprotective effects through bradykinin-dependent mechanisms than either drug
alone. (J Am Coll Cardiol 2002;40:162–6) © 2002 by the American College of Cardiology
Foundation
Angiotensin-converting enzyme (ACE) produces angioten-
sin II (1), a potent coronary vasoconstrictor. The ACE
inhibitors are reported to inhibit the degradation of brady-
kinin by inhibiting kinase II (2,3). Bradykinin generates
nitric oxide (NO) through B2 receptor activation (4,5),
which increases coronary blood flow (CBF) through B1
receptor activation (6,7), both of which contribute to an
increase in CBF (8). Accordingly, the concomitant admin-
istration of an ACE inhibitor and angiotensin II receptor
blocker (ARB) may cause further increases in CBF. How-
ever, the infarct size-limiting effect of both ACE inhibitors
and ARBs is reported to be blunted by HOE140 (9), and
the effects of ARBs are related to bradykinin (10), suggest-
ing that concomitant administration of ACE inhibitors and
ARBs may have overlapping effects on CBF in the ischemic
myocardium. In contrast, the interaction between bradykinin
and angiotensin II receptors was reported recently, which
involved heterodimerization with the activation of Gq and
Gi proteins (11). This suggests that antagonizing angiotensin
II release may increase the sensitivity of bradykinin receptors. If
this is the case, ARBs would potentiate ACE inhibitor- or
bradykinin-induced coronary vasodilation. At present, it is not
clear whether the coronary effects of either ACE inhibitors or
ARB are identical or different, and both drugs cause a further
increase in CBF in ischemic hearts.
To answer these questions, we tested the effects of an ACE
inhibitor, ARB or combined therapy on CBF in the ischemic
myocardium.
METHODS
Instrumentation. Twenty-nine beagle dogs weighing 11
to 15 kg were used. Each animal was anesthetized with
pentobarbital sodium (30 mg/kg intravenously). The meth-
ods for the preparation of the experiments were previously
described (2).
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Experimental protocols. PROTOCOL I: EFFECTS OF TE-
MOCAPRILAT OR RNH-6270, OR BOTH, ON MYOCARDIAL
ISCHEMIA PRODUCED BY CORONARY HYPOPERFUSION
(N  24). Coronary arterial and venous blood was sampled
for blood gas analysis and for determination of the levels of
lactate, plasma NO metabolites (i.e., nitrate and nitrite) and
bradykinin, as well as plasma ACE activity. After the dogs’
hemodynamics became stable, we infused either saline (n 
7, group A), HOE140 (n  7, group B) or N-nitro-L-
arginine methyl ester (L-NAME) (n  7, group C). Five
minutes after starting the infusion, coronary perfusion
pressure (CPP) was reduced by using an occluder attached
to the extracorporeal bypass tube, so that CBF was de-
creased to one-third of its control value. After low CPP was
reached, the occluder was adjusted precisely to keep the
CPP constant at this level. We have confirmed that 5 min
is required to obtain a stable state in the hypoperfused
myocardium. Once these measurements were obtained at
5 min, temocaprilat (10 g/kg/min; Sankyo K.K., Tokyo,
Japan) was infused into the left anterior descending coro-
nary artery (LAD), and all hemodynamic and metabolic
parameters were measured again after 10 min. The coronary
hemodynamic and metabolic parameters, as well regional
myocardial contraction, were studied at 10 min after starting
the infusion of temocaprilat or RNH-6270. After recording
all of the data, we discontinued the infusion of all drugs and
the occluder was released for 10 min. After confirming that
all of the hemodynamic and metabolic parameters had
returned to baseline levels, we again reduced the CPP and
decreased CBF to one-third of baseline. After 5 min,
RNH-6270 (10 g/kg/min; Sankyo K.K.) was infused for
10 min, and the protocol described earlier was repeated.
Finally, after discontinuation of drugs and release of the
occluder for 10 min, we again reduced the CPP and infused
RNH-6270 plus temocaprilat (both at 10 g/kg/min) for
10 min. The dose of temocaprilat or RNH-6270 was
determined as the minimal dose that caused maximal
vasodilation.
PROTOCOL II: EFFECT OF TEMOCAPRILAT OR RNH-6270 ON
BRADYKININ-INDUCED CORONARY VASODILATION (N  5).
We infused saline, one of three doses of RNH-6270 (3.3,
6.7 or 10 g/kg/min) or one dose of temocaprilat
(10 g/kg/min). In each group, we measured CBF and CPP
during the infusion of three doses of bradykinin (5, 10 and
20 g/kg/min).
Assays. Lactate levels were measured by an enzymatic
assay, and the lactate extraction ratio (LER) was calculated
as the coronary arteriovenous difference of the lactate
concentration multiplied by 100 and divided by the arterial
lactate concentration. The method used for measurement of
bradykinin has been described previously (12). The total
amount of plasma NO metabolites (i.e., nitrate and nitrite)
was analyzed by an automated procedure based on the
Griess reaction (13). The differences of the nitrate and
nitrite concentrations between coronary venous and arterial
blood were used to quantify the cardiac NO level. The
method used for measurement of plasma ACE activity has
been described previously (14).
Statistical analysis. Statistical analysis was performed with
repeated measures analysis of variance, followed by the
modified Bonferroni multiple comparison (15,16). All re-
sults are expressed as the mean value  SEM, and a value
of p  0.05 was considered significant.
RESULTS
The mean blood pressure (102  2 mm Hg) and heart rate
(142  2 beats/min) did not differ significantly between the
groups (p  0.76) or before and during coronary hypoper-
fusion with or without pharmacologic intervation (p 
0.59).
Effects of ACE inhibitors and/or ARB on CBF. Figure 1
shows the CBF profile before and during the reduction of
CPP (43  1 mm Hg in group A, 45  1 mm Hg in group
B and 46  2 mm Hg in group C) with or without
pharmacologic intervention. RNH-6270 increased CBF,
but temocaprilat increased CBF (p  0.01) more. Both
RNH-6270 and temocaprilat further increased CBF (p 
0.01). The increase in CBF due to temocaprilat, but not
RNH-6270, was blunted by either HOE140 or L-NAME
(p  0.01). Interestngly, the synergistic increase in CBF
cause by RNH-6270 plus temocaprilat was blunted by either
HOE140 or L-NAME (p  0.01). RNH-6270 and temo-
caprilat increased the percent CBF to 40% and 10%,
respectively, which predicted that administration of both
agents could cause an increase of50% in CBF. In fact, the
combination of RNH-6270 and temocaprilat caused a 70%
increase in CBF. The severity of myocardial ischemia, based
on the changes of regional fractional shortening and LER,
was parallel with the changes in CBF (data not shown).
Temocaprilat caused a marked decrease in plasma ACE
activity in coronary venous blood (from 5.9  0.7 to 0.12 
0.04 IU/l) during coronary hypoperfusion (p  0.01). In
contrast, RNH-6270 did not decrease the plasma ACE
activity (6.3  0.5 IU/l), and the combination of temoca-
prilat plus RNH-6270 did not cause a further decrease in
ACE activity (0.15  0.06 IU/l).
Figures 2 and 3 show the cardiac levels of NO and
bradykinin. The cardiac NO level was increased by temo-
caprilat (p  0.01) but not by RNH-6270. Interestingly,
both RNH-6270 and temocaprilat caused a further increase
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in cardiac NO levels (p  0.01). Because the CBF response
was identical to the changes in the cardiac NO level and
L-NAME blunted (p  0.01) the synergistic increase in
CBF in the RNH-6270 plus temocaprilat group, bradykinin
may have been increased in this group, as compared with its
level in the temocaprilat group. However, the bradykinin
level seen after administration of temocaprilat was not
enhanced in the RNH-6270 plus temocaprilat group, al-
Figure 1. Coronary blood flow (CBF) before the reduction of coronary perfusion pressure (C) and during myocardial ischemia with (I  Drug) or without
(I) RNH-6270, temocaprilat or both. The results were obtained with saline (left), HOE140 (middle) or N-nitro-L-arginine methyl ester (L-NAME)
(right) infusion.
Figure 2. Nitric oxide (NOx) (cardiac NO2
  NO3
) level before the reduction of coronary perfusion pressure (C) and during myocardial ischemia with
(IDrug) or without (I) RNH-6270, temocaprilat or both. The results were obtained with saline (left), HOE140 (middle) or N-nitro-L-arginine methyl
ester (L-NAME) (right) infusion.
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though the enhancement of CBF in this group was com-
pletely blocked by HOE140 (p  0.01). To explain this
discrepancy, we hypothesized that RNH-6270 may enhance
the CBF response to bradykinin produced by temocaprilat.
When we tested this hypothesis, we found that bradykinin-
induced coronary vasodilation was enhanced by RNH-6270
but not by temocaprilat (Fig. 4).
DISCUSSION
Augmentation of bradykinin-induced coronary vasodila-
tion by ARB. We showed that ARB could enhance ACE
inhibitor-induced NO production and cause increases in
CBF in the ischemic myocardium. We first thought that the
addition of an ARB might cause a slight increase in the
cardiac bradykinin level and thus raise the NO level. Indeed,
Tsutsumi et al. (10) observed bradykinin-induced increases
in NO and cyclic guanosine monophosphate in the aorta of
mice. However, we showed that an ARB plus ACE inhib-
itor did not increase cardiac bradykinin levels. This result
may seem to be contradictory, but it can be explained as
follows. First, the species, target tissue and experimental
conditions were different between the Tsutsumi et al. (10)
study and the present study. Tsutsumi et al. (10) adminis-
tered an ARB to the isolated aorta of mice, whereas we
infused it into the coronary artery of dogs with ischemic
myocardium. Also, because we observed that an ARB can
enhance bradykinin-induced increases in CBF, if bradyki-
nin was present in the experiment of Tsutsumi et al. (10),
the present result predicts that an ARB increases cyclic
guanosine monophosphate levels even in the isolated aorta.
In ischemic heart, cardiac NO production was partially
attenuated by either L-NAME or HOE140, suggesting that
bradykinin contributes to the production of NO due to
ischemic stress. Furthermore, cardiac bradykinin levels were
augmented by HOE140 in ischemic hearts. This suggests
that the blockade or stimulation of bradykinin receptors
augments or reduces cardiac bradykinin production, respec-
tively.
Although the cellular mechanisms remain unclear, this is
the first evidence, to the best of our knowledge, that ARB
infusion enhances bradykinin-induced coronary vasodilation
and that it increases ACE inhibitor-induced bradykinin-
mediated coronary vasodilation.
Study limitations. The major assumption in all of the
experimental protocols used in the present study was that
intracoronary infusion of agents such as temocaprilat,
RNH-6270, L-NAME and HOE-140 did not have any
effect on the peripheral vessels and that the observed
changes in the LAD territory also were only due to a local
effect on the coronary vasculature. If our pharmacologic
interventions in the LAD territory also had an influence on
systemic hemodynamics, the beneficial effects of temocap-
Figure 3. Cardiac bradykinin (BK) levels before the reduction of coronary perfusion pressure (C) and during myocardial ischemia with (I  Drug) or
without (I) RNH-6270, temocaprilat or both. The results were obtained with saline (A), HOE140 (B) or N-nitro-L-arginine methyl ester (L-NAME)
(C) infusion.
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rilat or RNH-6270 may have been secondary to systemic
vascular effects, such as afterload reduction. However, in the
preliminary study, we observed that systemic vascular resis-
tance is not altered by temocaprilat or RNH-6270 in
ischemic hearts (data not shown).
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Figure 4. Coronary blood flow before and during the infusion of three
doses of bradykinin with and without either RNH-6270 or temocaprilat.
RNH-6270 enhanced the bradykinin-induced increase in coronary blood
flow. C  coronary perfusion pressure; Drug  with RNH-6270.
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